Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADORE-BARI: Baricitinib versus placebo in polymyalgia rheumatica
2024-518385-26-01Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Oct 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Baricitinib (Olumiant) with Placebo (2 arms). Planned start Oct 2025; status: authorised.
02
Drugs
baricitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-518385-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518385-26-01.